STAMFORD, Conn., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at three upcoming conferences.
Details of the conferences are as follows:
- Stifel 2015 Healthcare Conference, November 17, 2015 at 4:30 pm Eastern Time, Lotte New York Palace, New York, NY
- Piper Jaffray 27th Annual Healthcare Conference, December 1, 2015 at 8:00 am Eastern Time, Lotte New York Palace, New York, NY
- Oppenheimer 26th Annual Healthcare Conference, December 9, 2015 at 2:10 pm Eastern Time, Westin New York Grand Central, New York, NY
Live webcasts of the presentations will be available at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Jacob S. Van Naarden
Vice President, Corporate Development and Strategy
The Trout Group, LLC
Loxo Oncology, Inc.
Pure Communications, Inc.